Excerpt from our Wall Street Breakfast, a one-page summary of this morning's key market-moving and stock-moving stories:
Tool May Lead To Genetic 'Scoring' [StarTribune.com]
Summary: Fair Isaac, the company behind credit scores (“FICO scores”) is going biotech. Using the same data mining and statistical techniques employed in its credit score, Fair Isaac has introduced its first commercial product to come out of its four year old bioanalytics division. FICO’s FlatPanel Diagnostics will allow veterinarians to test cats for multiple diseases based on a single DNA sample. Previously the vet would have to test for each disease individually. Fair Isaac hopes to use this technology to eventually develop diagnostic tools for humans that will both detect diseases and recommend the best treatment.
Related links: RNA Interference Technology's "Home Run" Potential • Quest Diagnostics Gets Much Cheaper - But is It Now Cheap? • Test Tube Steaks?
Potentially impacted stocks and ETFs: Fair Isaac (FIC)
Seeking Alpha is not affiliated with StarTribune.com.